Enhua Pharmaceutical announced that Enhua Hexin, a wholly-owned subsidiary of the company, signed an “Exclusive Commercial Cooperation Agreement” with Luye Pharmaceutical and Luye Jiao to obtain exclusive commercial rights for three long-acting antipsychotic injections in mainland China: injectable risperidone microspheres, paliperidone palmitate injection, and paliperidone palmitate injection. The cooperation period is until December 31, 2035. Enwa and Credit are required to pay a one-time authorized consideration of 20 million US dollars to complete sales of at least 2.7 billion yuan from 2026 to 2035. If the promised sales amount is achieved, priority negotiation rights are available within 2 months after the expiration date. This transaction does not constitute a related or major asset restructuring.

Enhua Pharmaceutical announced that Enhua Hexin, a wholly-owned subsidiary of the company, signed an “Exclusive Commercial Cooperation Agreement” with Luye Pharmaceutical and Luye Jiao to obtain exclusive commercial rights for three long-acting antipsychotic injections in mainland China: injectable risperidone microspheres, paliperidone palmitate injection, and paliperidone palmitate injection. The cooperation period is until December 31, 2035. Enwa and Credit are required to pay a one-time authorized consideration of 20 million US dollars to complete sales of at least 2.7 billion yuan from 2026 to 2035. If the promised sales amount is achieved, priority negotiation rights are available within 2 months after the expiration date. This transaction does not constitute a related or major asset restructuring.